English

QLIFE HOLDING AB INTERIM REPORT Q2, 2021

Report this content

Successful capital raise and sales partnership

FINANCIAL SUMMARY – SECOND QUARTER 2021

  • Revenue in the period amounted to kSEK 10,482 (6,181). Sales regards COVID-19 tests from the test service center as well as Egoo.Health devices and capsules for decentralized testing.
  • EBITDA for the period amounted to kSEK -8,107 (-2,147), and net loss kSEK -11,327 (-1,138).
  • The positive cash flow is related to the new issue of shares and exercise of warrants (TO1).
  • The total cash flow in the second quarter amounted to kSEK 98,771 (-5,774).
  • Earnings per share before/after dilution for the second quarter amounted to SEK -0.85 (-0.10), calculated on weighted average number of shares in the period.

 FINANCIAL SUMMARY – JANUARY -JUNI 2021

  • Revenue in the period amounted to kSEK 21,658 (6,566). Revenue regards sales of COVID-19 tests from the test service center as well as Egoo.Health devices and capsules for decentralized testing.
  • EBITDA for the period amounted to kSEK -11,304 (-7,879), and net loss kSEK -18,034 (-9,841).
  • The positive cash flow is related to the new issue of shares and exercise of warrants (TO1).
  • The total cash flow in the six months period amounted to kSEK 87,487 (27,980).
  • Shareholders equity as of 30 June amounted to kSEK 193,208 (101,775).
  • Earnings per share before/after dilution for the six months amounted to SEK -1.47 (-0.99), calculated on weighted average number of shares in the period.

SIGNIFICANT EVENTS – SECOND QUARTER 2021

  • Qlife signed an exclusive distribution agreement with Aidian. OY for the Egoo. Health device and Sars-CoV-2 tests for the clinical market in a range of European countries. The agreement is initially for three years, and the value for the first 12 months period is estimated to be approximately 40-50 MSEK.
  • Qlife expanded its test capacity during the European Football Championship to help implement safe arrangements for the matches played in Copenhagen.
  • Qlife carried out a directed share issue of approximately 90 MSEK, mainly to strategic and institutional investors, among others Fjärde AP-fonden, Strand Kapitalförvaltning, Eiffel Investment Group, Nyenburgh Holding and MW Asset Management. Subscription price for the shares was SEK 42 per share.
  • Qlife Holding AB announced the outcome of the exercise of the warrants of series TO1 that were issued in connection with the Company’s issue of units in February 2020. In total, 4,356,436 warrants of series TO 1 were exercised, corresponding to approximately 97.4 percent of the total number of outstanding warrants, for subscription of 2,178,218 shares at a subscription price of SEK 17.50 per share. Through the exercise of the warrants, Qlife received 38.1 MSEK before issuing costs amounting to 1.1 MSEK.
  • Qlife discontinued a development program at the oncology department at Herlev Hospital, intended to validate home monitoring of kidney cancer patients, due to the change in strategy followed by the Covid pandemic outbreak.
  • The annual general meeting 5 May resolved in accordance with the proposal from the Nomination Committee to re-elect Mette Gross, John Moll, Niklas Marschall and Thomas Warthoe as board members, and to elect Mette-Marie Harild, Ulrik Harrysson and Mikael Persson as new board members. Mette Gross was re-elected as chairman of the board of directors.

SIGNIFICANT EVENTS AFTER END OF SECOND QUARTER 2021

  • Qlife announced in July that a scientific study of the company’s COVID-19 test has been submitted to Natures Scientific Reports for publication. The study demonstrates the potential of Qlife’s mobile test platform Egoo.Health and COVID-19 tests that can deliver exactly the same clinical quality as laboratory tests in 30 minutes.

Link to report: https://qlifeholding.com/en/investors/finansiella-rapporter

This disclosure contains information that Qlife Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 16-08-2021 08:30 CET.

For more information please contact:

Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34

Qlife is a medical device company that seeks to revolutionize the clinical biomarker market for whole blood testing by taking it out of the lab and into the homes. This will facilitate easy access to blood sample results and in turn facilitate increased monitoring of parameters that enables care improvement.

Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor (phone: +46 (0) 8-503 000 50, e-mail: ca@gwkapital.se).

Read more on Egoo.health, Qlifeholding.com or follow us on LinkedIn.

 

Subscribe

Documents & Links